Tags

Type your tag names separated by a space and hit enter

Telmisartan and cardioprotection.
Vasc Health Risk Manag 2011; 7:677-83VH

Abstract

Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions, as revealed with the angiotensin converting enzyme (ACE) inhibitors trials. The angiotensin receptor blockers' (ARBs) efficacy in lowering blood pressure has been very well established. Telmisartan is however the first ARB to show a promising role in reducing cardiovascular risk in high-risk patients. This article will highlight the role of telmisartan in cardioprotection, underlying specifically the results of two major randomized controlled trials: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease).

Authors+Show Affiliations

State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22140319

Citation

Akhrass, Philippe R., and Samy I. McFarlane. "Telmisartan and Cardioprotection." Vascular Health and Risk Management, vol. 7, 2011, pp. 677-83.
Akhrass PR, McFarlane SI. Telmisartan and cardioprotection. Vasc Health Risk Manag. 2011;7:677-83.
Akhrass, P. R., & McFarlane, S. I. (2011). Telmisartan and cardioprotection. Vascular Health and Risk Management, 7, pp. 677-83. doi:10.2147/VHRM.S9447.
Akhrass PR, McFarlane SI. Telmisartan and Cardioprotection. Vasc Health Risk Manag. 2011;7:677-83. PubMed PMID: 22140319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Telmisartan and cardioprotection. AU - Akhrass,Philippe R, AU - McFarlane,Samy I, Y1 - 2011/11/15/ PY - 2011/12/6/entrez PY - 2011/12/6/pubmed PY - 2012/4/20/medline KW - ONTARGET KW - TRANSCEND KW - cardioprotection KW - telmisartan SP - 677 EP - 83 JF - Vascular health and risk management JO - Vasc Health Risk Manag VL - 7 N2 - Cardiovascular risk reduction has been the target of several large clinical trials in the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has been suggested to be among the most efficient cardioprotective interventions, as revealed with the angiotensin converting enzyme (ACE) inhibitors trials. The angiotensin receptor blockers' (ARBs) efficacy in lowering blood pressure has been very well established. Telmisartan is however the first ARB to show a promising role in reducing cardiovascular risk in high-risk patients. This article will highlight the role of telmisartan in cardioprotection, underlying specifically the results of two major randomized controlled trials: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease). SN - 1178-2048 UR - https://www.unboundmedicine.com/medline/citation/22140319/Telmisartan_and_cardioprotection_ L2 - https://dx.doi.org/10.2147/VHRM.S9447 DB - PRIME DP - Unbound Medicine ER -